Mortality in COPD: Inevitable or Preventable? Insights from the Cardiovascular Arena

REFERENCES

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId =989 (accessed May 2007)Updated 2006
   Google Scholar
• Balasubramanian V P, Varkey B. Chronic obstructive pulmonary disease: effects beyond the lungs. Curr Opin Pulm Med 2006; 12: 106–112
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2006, http://www.who.int/respiratory/copd/burden/en/index.html(accessed October 2006)COPD:Burden
   Google Scholar
• Mathers C D, Loncar D. Updated projections of global mortality and burden of disease. October, 2005, http://www.who.int/healthinfo/statistics/bodprojectionspaper.pdf (accessed August 2006)2002–2030: data sources, methods and results. Evidence and information for policy, World Health Organization
   Google Scholar
• Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970–2002. JAMA 2005; 294: 1255–1259
   PubMed Web of Science ®Google Scholar
• Unal B, Critchley J A, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 2004; 109: 1101–1107
   PubMed Web of Science ®Google Scholar
• Unal B, Critchley J A, Capewell S. Modelling the decline in coronary heart disease deaths in England and Wales, 1981–2000: comparing contributions from primary prevention and secondary prevention. BMJ 2005; 331: 614
   PubMed Web of Science ®Google Scholar
• Ramsay S E, Whincup P H, Lawlor D A, Papacosta O, Lennon L T, Thomas M C, Ebrahim S, Morris R W. Secondary prevention of coronary heart disease in older patients after the national service framework: population based study. BMJ 2006; 332: 144–145
   PubMed Web of Science ®Google Scholar
• Pedersen T R, Wilhelmsen L, Faergeman O, Strandberg T E, Thorgeirsson G, Troedsson L, Kristianson J, Berg K, Cook T J, Haghfelt T, Kjekshus J, Miettinen T, Olsson A G, Pyorala K, Wedel H. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol 2000; 86: 257–262
   PubMed Web of Science ®Google Scholar
• West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440–1445
   PubMed Web of Science ®Google Scholar
• Koren M J, Hunninghake D B. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol 2004; 44: 1772–1779
   PubMed Web of Science ®Google Scholar
• Anthonisen N R, Skeans M A, Wise R A, Manfreda J, Kanner R E, Connett J E. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233–239
   PubMed Web of Science ®Google Scholar
• Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93: 391–398
   PubMed Web of Science ®Google Scholar
• Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1: 681–686
   PubMed Web of Science ®Google Scholar
• Gan W Q, Man S F, Senthilselvan A, Sin D D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574–580
   PubMed Web of Science ®Google Scholar
• Sidney S, Sorel M, Quesenberry C P, Jr., De Luise C, Lanes S, Eisner M D. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068–2075
   PubMed Web of Science ®Google Scholar
• Donaldson G C, Seemungal T A, Patel I S, Bhowmik A, Wilkinson T M, Hurst J R, Maccallum P K, Wedzicha J A. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005; 128: 1995–2004
   PubMed Web of Science ®Google Scholar
• Man S F, Connett J E, Anthonisen N R, Wise R A, Tashkin D P, Sin D D. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006; 61: 849–853
   PubMed Web of Science ®Google Scholar
• Sin D D, Tu J V. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 580–584
   PubMed Web of Science ®Google Scholar
• Soriano J B, Vestbo J, Pride N B, Kiri V, Maden C, Maier W C. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002; 20: 819–825
   PubMed Web of Science ®Google Scholar
• Sin D D, Man S F. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter?. Eur Respir J 2003; 21: 260–266
   PubMed Web of Science ®Google Scholar
• Tkacova R, Toth S, Sin D D. Inhaled corticosteroids and survival in COPD patients receiving long-term home oxygen therapy. Respir Med 2006; 100: 385–392
   PubMed Web of Science ®Google Scholar
• Sin D D, Wu L, Anderson J A, Anthonisen N R, Buist A S, Burge P S, Calverley P M, Connett J E, Lindmark B, Pauwels R A, Postma D S, Soriano J B, Szafranski W, Vestbo J. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992–997
   PubMed Web of Science ®Google Scholar
• Macie C, Wooldrage K, Manfreda J, Anthonisen N R. Inhaled corticosteroids and mortality in COPD. Chest 2006; 130: 640–646
   PubMed Web of Science ®Google Scholar
• Soriano J B, Kiri V A, Pride N B, Vestbo J. Inhaled corticosteroids with/without long-acting β -agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Crit Care Med 2003; 2: 67–74
   Google Scholar
• Mapel D W, Hurley J S, Roblin D, Roberts M, Davis K J, Schreiner R, Frost F J. Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists. Respir Med 2006; 100: 595–609
   PubMed Web of Science ®Google Scholar
• Calverley P, Jones P, Larsson T, et al. Preventing mortality in COPD: the value of inhaled budesonide added to bronchodilators. Poster presented at Fifth International Multidisciplinary Conference on Chronic Obstructive Pulmonary Disease (COPD5). BirminghamUK Jun 28-30, 2006, Abstract 35
   Google Scholar
• Mapel D W. Treatment implications on morbidity and mortality in COPD. Chest 2004; 126: 150S–158S
   PubMedGoogle Scholar
• Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74–81
   PubMed Web of Science ®Google Scholar
• Calverley P M, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912–919
   PubMed Web of Science ®Google Scholar
• Halpin D M. Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: the value of NNT analysis. Int J Clin Pract 2005; 59: 1187–1194
   PubMed Web of Science ®Google Scholar
• Gudmundsson G, Gislason T, Lindberg E, Hallin R, Ulrik C S, Brondum E, Nieminen M M, Aine T, Bakke P, Janson C. Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir Res 2006; 7: 109
   PubMed Web of Science ®Google Scholar
• Sin D D, Man S F. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2: 8–11
   PubMedGoogle Scholar
• Hansell A L, Walk J A, Soriano J B. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J 2003; 22: 809–814
   PubMed Web of Science ®Google Scholar
• National Institutes of Health: National Heart, Lung and Blood Institute. Morbidity & mortality: 2004 chartbook on cardiovascular, lung, and blood diseases, http://www.nhlbi.nih.gov/resources/docs/04_chtbk.pdf (accessed September 2006)
   Google Scholar
• Pauwels R A, Rabe K F. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364: 613–620
   PubMed Web of Science ®Google Scholar
• Jensen H H, Godtfredsen N S, Lange P, Vestbo J. Potential misclassification of causes of death from COPD. Eur Respir J 2006; 28: 781–785
   PubMed Web of Science ®Google Scholar
• Mannino D M, Brown C, Giovino G A. Obstructive lung disease deaths in the United States from 1979 through 1993. An analysis using multiple-cause mortality data. Am J Respir Crit Care Med 1997; 156: 814–818
   PubMed Web of Science ®Google Scholar
• Mehta R H, Roe M T, Chen A Y, Lytle B L, Pollack C V, Jr., Brindis R G, Smith S C, Jr., Harrington R A, Fintel D, Fraulo E S, Califf R M, Gibler W B, Ohman E M, Peterson E D. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Intern Med 2006; 166: 2027–2034
   PubMed Web of Science ®Google Scholar
• Ramsey S D, Hobbs F D. Chronic obstructive pulmonary disease, risk factors, and outcome trials: comparisons with cardiovascular disease. Proc Am Thorac Soc 2006; 3: 635–640
   PubMedGoogle Scholar
• Halpin D M, Miravitlles M. Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc 2006; 3: 619–623
   PubMedGoogle Scholar
• Agusti A G. COPD, a multicomponent disease: implications for management. Respir Med 2005; 99: 670–682
   PubMed Web of Science ®Google Scholar
• Frohlich M, Sund M, Lowel H, Imhof A, Hoffmeister A, Koenig W. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J 2003; 24: 1365–1372
   PubMed Web of Science ®Google Scholar
• De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflammation markers predicting frailty and mortality in the elderly. Exp Mol Pathol 2006; 80: 219–227
   PubMed Web of Science ®Google Scholar
• Minas M, Dimitropoulos K, Pastaka C, Papadopoulos D, Markoulis N, Gourgoulianis K I. Global initiative for chronic obstructive lung disease for chronic obstructive pulmonary disease: GOLD opportunity for lung disorders. Prev Med 2005; 40: 274–277
   PubMed Web of Science ®Google Scholar
• Fuso L, Incalzi R A, Pistelli R, Muzzolon R, Valente S, Pagliari G, Gliozzi F, Ciappi G. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995; 98: 272–277
   PubMed Web of Science ®Google Scholar
• Vestbo J, Prescott E, Lange P, Schnohr P, Jensen G. Vital prognosis after hospitalization for COPD: a study of a random population sample. Respir Med 1998; 92: 772–776
   PubMed Web of Science ®Google Scholar
• Hansen E F, Phanareth K, Laursen L C, Kok-Jensen A, Dirksen A. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1267–1271
   PubMed Web of Science ®Google Scholar
• Martinez F J, Foster G, Curtis J L, Criner G, Weinmann G, Fishman A, DeCamp M M, Benditt J, Sciurba F, Make B, Mohsenifar Z, Diaz P, Hoffman E, Wise R. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med 2006; 173: 1326–1334
   PubMed Web of Science ®Google Scholar
• Hansen E F, Vestbo J, Phanareth K, Kok-Jensen A, Dirksen A. Peak flow as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 690–693
   PubMed Web of Science ®Google Scholar
• Nishimura K, Tsukino M. Clinical course and prognosis of patients with chronic obstructive pulmonary disease. Curr Opin Pulm Med 2000; 6: 127–132
   PubMedGoogle Scholar
• Schols A M, Slangen J, Volovics L, Wouters E F. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1791–1797
   PubMed Web of Science ®Google Scholar
• Landbo C, Prescott E, Lange P, Vestbo J, Almdal T P. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1856–1861
   PubMed Web of Science ®Google Scholar
• Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003; 167: 544–549
   PubMed Web of Science ®Google Scholar
• Celli B R, Cote C G, Marin J M, Casanova C, Montes de Oca M, Mendez R A, Pinto Plata V, Cabral H J. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005–1012
   PubMed Web of Science ®Google Scholar
• Cote C G. Surrogates of mortality in chronic obstructive pulmonary disease. Am J Med 2006; 119: S54–62
   PubMed Web of Science ®Google Scholar
• Santo Tomas L H, Varkey B. Improving health-related quality of life in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2004; 10: 120–127
   PubMed Web of Science ®Google Scholar
• Domingo-Salvany A, Lamarca R, Ferrer M, Garcia-Aymerich J, Alonso J, Felez M, Khalaf A, Marrades R M, Monso E, Serra-Batlles J, Anto J M. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 680–685
   PubMed Web of Science ®Google Scholar
• Jones P, Calverley P, Larsson T, et al. St George's Respiratory Questionnaire (SGRQ) scores may help identify COPD patients at increased risk of death over 1 year. Poster presented at the Fifth International Multidisciplinary Conference on Chronic Obstructive Pulmonary Disease (COPD5). BirminghamUK Jun 28-30, 2006, Abstract 34
   Google Scholar
• Fan V S, Curtis J R, Tu S P, McDonell M B, Fihn S D. Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases. Chest 2002; 122: 429–436
   PubMed Web of Science ®Google Scholar
• Yohannes A M, Baldwin R C, Connolly M J. Predictors of 1-year mortality in patients discharged from hospital following acute exacerbation of chronic obstructive pulmonary disease. Age Ageing 2005; 34: 491–496
   PubMed Web of Science ®Google Scholar
• Sprenkle M D, Niewoehner D E, Nelson D B, Nichol K L. The Veterans Short Form 36 questionnaire is predictive of mortality and health-care utilization in a population of veterans with a self-reported diagnosis of asthma or COPD. Chest 2004; 126: 81–89
   PubMed Web of Science ®Google Scholar
• Doll H, Miravitlles M, Health-related Q OL. in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics 2005; 23: 345–363
   PubMed Web of Science ®Google Scholar
• Soler-Cataluna J J, Martinez-Garcia M A, Roman S P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925–931
   PubMed Web of Science ®Google Scholar
• Almagro P, Calbo E, Ochoa de Echaguen A, Barreiro B, Quintana S, Heredia J L, Garau J. Mortality after hospitalization for COPD. Chest 2002; 121: 1441–1448
   PubMed Web of Science ®Google Scholar
• Eriksen N, Hansen E F, Munch E P, Rasmussen F V, Vestbo J. Chronic obstructive pulmonary disease. Admission, course and prognosis. Ugeskr Laeger 2003; 165: 3499–3502
   PubMedGoogle Scholar
• Groenewegen K H, Schols A M, Wouters E F. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124: 459–467
   PubMed Web of Science ®Google Scholar
• Connors A F, Jr., Dawson N V, Thomas C, Harrell F E, Jr., Desbiens N, Fulkerson W J, Kussin P, Bellamy P, Goldman L, Knaus W A. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154: 959–967
   PubMed Web of Science ®Google Scholar
• Roberts C M, Barnes S, Lowe D, Pearson M G. Evidence for a link between mortality in acute COPD and hospital type and resources. Thorax 2003; 58: 947–949
   PubMed Web of Science ®Google Scholar
• Danchin N, Blanchard D, Steg P G, Sauval P, Hanania G, Goldstein P, Cambou J P, Gueret P, Vaur L, Boutalbi Y, Genes N, Lablanche J M. Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry. Circulation 2004; 110: 1909–1915
   PubMed Web of Science ®Google Scholar
• Seemungal T A, Donaldson G C, Paul E A, Bestall J C, Jeffries D J, Wedzicha J A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418–1422
   PubMed Web of Science ®Google Scholar
• Kessler R, Stahl E, Vogelmeier C, Haughney J, Trudeau E, Lofdahl C G, Partridge M R. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest 2006; 130: 133–142
   PubMed Web of Science ®Google Scholar
• Donaldson G C, Seemungal T A, Bhowmik A, Wedzicha J A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–852
   PubMed Web of Science ®Google Scholar
• Wilkinson T M, Donaldson G C, Hurst J R, Seemungal T A, Wedzicha J A. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 1298–1303
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937–952
   PubMed Web of Science ®Google Scholar
• Braunwald E, Antman E M, Beasley J W, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). 2002, Available at http://www.acc.org/clinical/guidelines/unstable/unstable.pdf
   Google Scholar
• Keaney J F, Jr. Circulating biomarkers in acute coronary syndromes: something different or more of the same?. Circulation 2005; 112: 778–780
   PubMed Web of Science ®Google Scholar
• Chobanian A V, Bakris G L, Black H R, Cushman W C, Green L A, Izzo J L, Jr., Jones D W, Materson B J, Oparil S, Wright J T, Jr., Roccella E J. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–3421
   PubMed Web of Science ®Google Scholar
• Abroug F, Ouanes-Besbes L, Nciri N, Sellami N, Addad F, Hamda K B, Amor A B, Najjar M F, Knani J. Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med 2006; 174: 990–996
   PubMed Web of Science ®Google Scholar
• Barnes P J, Chowdhury B, Kharitonov S A, Magnussen H, Page C P, Postma D, Saetta M. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 6–14
   PubMed Web of Science ®Google Scholar
• Zaher C, Halbert R, Dubois R, George D, Nonikov D. Smoking-related diseases: the importance of COPD. Int J Tuberc Lung Dis 2004; 8: 1423–1428
   PubMed Web of Science ®Google Scholar
• Schiller J S, Ni H. Cigarette smoking and smoking cessation among persons with chronic obstructive pulmonary disease. Am J Health Promot 2006; 20: 319–323
   PubMed Web of Science ®Google Scholar
• Curkendall S M, Lanes S, de Luise C, Stang M R, Jones J K, She D, Goehring E, Jr. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur J Epidemiol 2006; 21: 803–813
   PubMed Web of Science ®Google Scholar
• Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003; 168: 49–53
   PubMed Web of Science ®Google Scholar
• Suissa S. Observational studies of inhaled corticosteroids in chronic obstructive pulmonary disease: misconstrued immortal time bias. Am J Respir Crit Care Med 2006; 173: 464–465
   PubMed Web of Science ®Google Scholar
• Burge P S, Calverley P M, Jones P W, Spencer S, Anderson J A, Maslen T K. For the ISOLDE study investigators. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 2000; 320: 1297–1303
   PubMed Web of Science ®Google Scholar
• Spencer S, Calverley P M, Sherwood B P, Jones P W. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 122–128
   PubMed Web of Science ®Google Scholar
• Spencer S, Calverley P M, Burge P S, Jones P W. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23: 698–702
   PubMed Web of Science ®Google Scholar
• Briggs A H, Lozano-Ortega G, Spencer S, Bale G, Spencer M D, Burge P S. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value Health 2006; 9: 227–235
   PubMed Web of Science ®Google Scholar
• Alsaeedi A, Sin D D, McAlister F A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113: 59–65
   PubMed Web of Science ®Google Scholar
• Lofdahl C G, Postma D, Pride N, Boe J, Thoren A. Does inhaled budesonide protect against cardio-ischaemic events in mild-moderate COPD: a post-hoc evaluation of the EUROSCOP study. Eur Resp J 2005; 26(Suppl. 49)360s
   Google Scholar
• Calverley P MA, Anderson J A, Celli B, Ferguson G T, Jenkins C, Jones P W, Yates J C, Vestbo J. For the TORCH investigators Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–789
   PubMed Web of Science ®Google Scholar
• Salpeter S R, Buckley N S, Salpeter E E. Meta-analysis: anticholinergics, but not β -agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 2006; 21: 1011–1019
   PubMed Web of Science ®Google Scholar
• Campbell S C, Criner G J, Levine B E, Simon S J, Smith J S, Orevillo C J, Ziehmer B A. Cardiac safety of formoterol 12mug twice daily in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2007; 20: 571–579
   PubMed Web of Science ®Google Scholar
• Rosenkranz B, Rouzier R, Kruse M, Dobson C, Ayre G, Horowitz A, Fitoussi S. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. Respir Med 2006; 100: 666–672
   PubMed Web of Science ®Google Scholar
• Goldkorn A, Diotto P, Burgess C, Weatherall M, Holt S, Beasley R, Siebers R. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol. Respirology 2004; 9: 102–108
   PubMed Web of Science ®Google Scholar
• Nelson H S. Long-acting beta-agonists in adult asthma: evidence that these drugs are safe. Prim Care Respir J 2006; 15: 271–277
   PubMedGoogle Scholar
• Nelson H S. Is there a problem with inhaled long-acting B-adrenergic agonists. J Allergy Clin Immunol 2006; 117: 3–16
   PubMed Web of Science ®Google Scholar
• Barr R G, Bourbeau J, Camargo C A, Ram F S. Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax 2006; 61: 854–862
   PubMed Web of Science ®Google Scholar
• Anzueto A, Tashkin D, Menjoge S, Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005; 18: 75–81
   PubMed Web of Science ®Google Scholar
• Decramer M, Celli B, Tashkin D P, Pauwels R A, Burkhart D, Cassino C, Kesten S. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: The Uplift trial. Journal of Chronic Obstructive Pulmonary Disease 2004; 1: 303–312
   Google Scholar
• Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449–456
   PubMed Web of Science ®Google Scholar
• Laupacis A, Sackett D L, Roberts R S. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318: 1728–1733
   PubMed Web of Science ®Google Scholar
• Cazzola M. Application of number needed to treat (NNT) as a measure of treatment effect in respiratory medicine. Treat Respir Med 2006; 5: 79–84
   PubMedGoogle Scholar
• Celli B, Calverley P M, Anderson J A, et al. The TOwards a Revolution in COPD Health (TORCH) study: Fluticasone propionate/Salmeterol reduces the rate of exacerbations over 3 years. Chest 2006; 130: 177s
   Web of Science ®Google Scholar
• Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe COPD. Am J Respir Crit Care Med 2007; 175: 144–149
   PubMed Web of Science ®Google Scholar
• Vestbo J. TORCH Study Group The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J 2004; 24: 206–210
   PubMed Web of Science ®Google Scholar
• Rabe K F. Treating COPD–the TORCH trial, P values, and the Dodo. New England Med 2007; 356: 851–854
   PubMed Web of Science ®Google Scholar
• Ferguson G T, Calverley P MA, Anderson J A, et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) is well tolerated in patients with COPD over three years. Eur Respir J 2006; 28(Suppl. 50)34s
   Google Scholar
• Brekke P H, Mahmood F, Soyseth V. Should patients with chronic obstructive pulmonary disease (COPD) be treated with statins after an exacerbation?. San Diego, CAUSA 2006; A122, ATS, 19–24 May, 2006
   Google Scholar
• Soyseth V, Brekke P H, Smith P, Omland T. Statin use is associated with reduced mortality in chronic obstructive pulmonary disease. Eur Respir J 2007; 29: 279–283
   PubMed Web of Science ®Google Scholar
• Mancini G B, Etminan M, Zhang B, Levesque L E, FitzGerald J M, Brophy J M. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47: 2554–2560
   PubMed Web of Science ®Google Scholar
• Younis W G, Chbeir E A, Daher N N, et al. Statins protect smokers from lung disease. Chest 2006; 130: 180s
   Google Scholar
• Resch U, Tatzber F, Budinsky A, Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 2006; 61: 262–274
   PubMed Web of Science ®Google Scholar
• Ridker P M, Cannon C P, Morrow D, Rifai N, Rose L M, McCabe C H, Pfeffer M A, Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20–28
   PubMed Web of Science ®Google Scholar
• Hothersall E, McSharry C, Thomson N C. Potential therapeutic role for statins in respiratory disease. Thorax 2006; 61: 729–734
   PubMed Web of Science ®Google Scholar
• Rembold C M. Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy. J Fam Pract 1996; 42: 577–586
   PubMed Web of Science ®Google Scholar
• Diener H C, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–153
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389
   PubMed Web of Science ®Google Scholar
• Bateman E D, Boushey H A, Bousquet J, Busse W W, Clark T J, Pauwels R A, Pedersen S E. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836–844
   PubMed Web of Science ®Google Scholar